Ajanta Pharma FY26 Annual Earnings Summary

Geopolitical tensions have increased freight costs and transit times; if prolonged, could impact Asia business recovery and margins.

Mark-to-market forex losses of ₹41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying margin performance.

Africa institutional (antimalarial) business remains dependent on unpredictable aid agency procurement, with revenue declining 17% in H1.

Asia branded revenue declined 9% YoY in Q3 due to softer traction in certain markets and shipment delays.

Analyst raised concern about intense competition in India GLP-1 market with 15-20+ players expected; management acknowledged but expects lower competition in emerging markets.

Five observations received; while management expects no immediate impact, any escalation could affect filings or existing product supplies.

Both markets are tender-driven and competitive; management factors erosion into guidance but unexpected acceleration could pressure margins.

Management acknowledged a gap between IQVIA-reported growth (6%) and internal sales growth (matching IPM's 12%) in cardiac, which could affect investor perception.

Trade receivables days increased to 101 from 94 due to switch from factoring to working capital loans, though management says it's P&L neutral.

9-month forex mark-to-market loss of ₹61 crore under other expenses, though no loss in Q3; currency movements remain a risk.

Additional provision of ₹7 crore made for new labor code liabilities; ongoing impact on staff costs.

Two promoter brothers have increased borrowing against shares for their own businesses, though no pledge on Ajanta shares; could raise governance concerns.